Fox Run Management, L.L.C. Aclaris Therapeutics, Inc. Transaction History

Fox Run Management, L.L.C.

  • $433 Million
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 07, 2023
BUY
$14.33 - $18.37 $20,377 - $26,122
1,422 Added 9.53%
16,350 $257,000
Q3 2022

Nov 07, 2022
BUY
$13.07 - $18.22 $195,108 - $271,988
14,928 New
14,928 $235,000
Q1 2022

May 10, 2022
SELL
$9.74 - $17.92 $188,644 - $347,074
-19,368 Closed
0 $0
Q4 2021

Feb 09, 2022
BUY
$12.27 - $18.49 $237,645 - $358,114
19,368 New
19,368 $282,000
Q2 2018

Jul 17, 2018
SELL
$16.46 - $20.33 $179,414 - $221,596
-10,900 Closed
0 $0
Q1 2018

Apr 17, 2018
BUY
$17.08 - $25.64 $186,171 - $279,476
10,900 New
10,900 $191,000

Others Institutions Holding ACRS

# of Institutions
84
Shares Held
50.7M
Call Options Held
30.6K
Put Options Held
1K
View Full List

About Aclaris Therapeutics, Inc.

ACRS Quotes by TradingView
  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $253M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email